pharmaphorum

APRIL 14, 2022

Established on the success of our RNA Therapeutics series, we look forward to welcoming you at Oligonucleotide Therapeutics and Delivery to join the conversation around maximizing the potential of oligo-based treatments.

RNA 52

RNA Clinical Trials Clinical Trials Life Science 52

pharmaphorum

OCTOBER 12, 2022

The payload, Del Bourgo tell us, is the therapeutic DNA or RNA sequence that will cure or fix damaged cells. Now, we can grow our R&D more rapidly and hire more business development and marketing colleagues to extend our reach to customers,” Del Bourgo says. About Whitelab Genomics.

Genome 105

Genome Genomics Medicine Development 105

The Pharma Data

AUGUST 3, 2021

Revenue growth was 12 percent when excluding effects of 2020 COVID-related stocking patterns, revenue from COVID-19 antibodies and recent business development. Business Development/Other Developments. In the second quarter of 2021, the company recognized acquired in-process research and development charges of $25.0

Antibody 52

Antibody Sales Development Production 52

The Pharma Data

JUNE 7, 2023

a biotechnology company specializing in the development of lipid nanoparticle (LNP) delivery systems for molecular therapeutics. Acuitas’ LNP technology will support Bayer’s in vivo gene editing and protein replacement programs by specifically delivering RNA payloads to the desired target organ, the liver.

Gene Therapy 40

Gene Therapy Gene Gene Editing In-Vivo 40

XTalks

AUGUST 2, 2023

They are committed to capitalizing on growth opportunities primarily through the advancement of their own product pipeline and constantly improving their existing products, as well as through business development activities. This stops the PARP from repairing any cancer cells, causing the cells to die. billion in 2022. billion in 2021.

Sales 98

Sales Manufacturing FDA Approval Life Science 98